Venture Associates L. Index III Sells 36,574 Shares of Minerva Neurosciences Inc (NERV) Stock

Share on StockTwits

Minerva Neurosciences Inc (NASDAQ:NERV) major shareholder Venture Associates L. Index III sold 36,574 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $7.05, for a total transaction of $257,846.70. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

NASDAQ NERV traded down $0.35 on Friday, reaching $5.93. 179,174 shares of the company’s stock traded hands, compared to its average volume of 142,838. The company has a market capitalization of $252.88 million, a PE ratio of -4.60 and a beta of 1.39. Minerva Neurosciences Inc has a fifty-two week low of $5.51 and a fifty-two week high of $12.95.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). As a group, equities analysts predict that Minerva Neurosciences Inc will post -1.62 earnings per share for the current year.

NERV has been the topic of a number of research analyst reports. Zacks Investment Research lowered shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Thursday, January 17th. BidaskClub downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 17th. Finally, ValuEngine downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th.

A number of hedge funds and other institutional investors have recently bought and sold shares of NERV. Bank of New York Mellon Corp lifted its position in Minerva Neurosciences by 22.2% during the third quarter. Bank of New York Mellon Corp now owns 126,840 shares of the biopharmaceutical company’s stock valued at $1,592,000 after purchasing an additional 23,059 shares during the period. BlackRock Inc. lifted its position in Minerva Neurosciences by 12.2% during the third quarter. BlackRock Inc. now owns 2,448,326 shares of the biopharmaceutical company’s stock valued at $30,727,000 after purchasing an additional 266,623 shares during the period. Renaissance Technologies LLC lifted its position in Minerva Neurosciences by 72.3% during the third quarter. Renaissance Technologies LLC now owns 303,200 shares of the biopharmaceutical company’s stock valued at $3,805,000 after purchasing an additional 127,200 shares during the period. MetLife Investment Advisors LLC lifted its position in Minerva Neurosciences by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 25,297 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 8,993 shares during the period. Finally, TIAA CREF Investment Management LLC lifted its position in Minerva Neurosciences by 23.4% during the third quarter. TIAA CREF Investment Management LLC now owns 209,195 shares of the biopharmaceutical company’s stock valued at $2,625,000 after purchasing an additional 39,721 shares during the period. Institutional investors own 76.29% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://weekherald.com/2019/05/17/venture-associates-l-index-iii-sells-36574-shares-of-minerva-neurosciences-inc-nerv-stock.html.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Read More: Book Value Per Share in Stock Trading

Insider Buying and Selling by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.